KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Interest & Investment Income (2016 - 2025)

Abbott Laboratories' Interest & Investment Income history spans 17 years, with the latest figure at $78.0 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 14.29% year-over-year to $78.0 million; the TTM value through Dec 2025 reached $308.0 million, down 10.47%, while the annual FY2025 figure was $308.0 million, 10.47% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $78.0 million at Abbott Laboratories, up from $77.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $101.0 million in Q1 2023 and bottomed at $10.0 million in Q3 2021.
  • The 5-year median for Interest & Investment Income is $79.0 million (2024), against an average of $63.2 million.
  • The largest annual shift saw Interest & Investment Income plummeted 38.89% in 2021 before it surged 700.0% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $11.0 million in 2021, then soared by 700.0% to $88.0 million in 2022, then grew by 1.14% to $89.0 million in 2023, then rose by 2.25% to $91.0 million in 2024, then dropped by 14.29% to $78.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Interest & Investment Income are $78.0 million (Q4 2025), $77.0 million (Q3 2025), and $71.0 million (Q2 2025).